Brought to you by:
Innovation in vascular surgery: Balancing progress with patient safety
A debate at this year’s European Society for Vascular Surgery (ESVS 2024) annual meeting (Sept. 24–27) in Kraków, Poland, centered on innovation in vascular surgery, with experts considering whether it will “change everything.” While Matt Thompson, MBBS, chief executive officer…
Endologix announces 36-month results of DETOUR2 study
Endologix has announced the final 36-month results from the DETOUR2 study—a prospective, single-arm, international, multicentre clinical evaluation of the novel Detour system for fully percutaneous femoropopliteal bypass procedures. A press release details that the findings highlight the durable efficacy of…
Interim analysis provides early window into real-world Alto stent graft outcomes
In a podium-first presentation on the final day of the 2024 Charing Cross (CX) International Symposium (23–25 April, London, UK), Sean Lyden (Cleveland Clinic, Cleveland, USA) disclosed an interim analysis from the JAGUAR trial and, in doing so, gave delegates…
Endologix initiates postmarket study of the Detour system
Endologix has announced the initiation of the Percutaneous transmural arterial bypass (PTAB)1 postmarket study. This study marks the beginning of a comprehensive postmarket study aimed at evaluating the real-world performance of the Detour system in patients undergoing treatment for long…
Centers for Medicare & Medicaid Services grants Transitional Pass-Through payment for Endologix’s Detour system
Endologix recently announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Transitional Pass-Through (TPT) payment for the Detour system, effective since 1 January 2024. The TPT payment was created to facilitate patient access for qualifying new…
DETOUR1 and DETOUR2 pooled analysis of bypass system reveals primary rate of 68.1% through 24 months
Endologix has announced results from a pooled analysis of the DETOUR1 and DETOUR2 studies evaluating percutaneous transmural arterial bypass (PTAB) with the Detour system. The Detour system offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to bypass…
Endologix announces first patients treated with the Detour system
Endologix has shared in a press release that the first patients underwent percutaneous transmural arterial bypass (PTAB) using the Detour system since Food and Drug Administration (FDA) approval of the system was granted. PTAB with the Detour system treats complex peripheral…
Five-year results of the LEOPARD trial published in the Journal of Vascular Surgery
Endologix has announced the online publication of the final five-year results of the LEOPARD trial in the Journal of Vascular Surgery (JVS). The study’s findings showed that there was no significant difference in aneurysm-related outcomes between patients randomized to the…
The top 10 most popular Vascular Specialist stories of December 2022
Among the most-read Vascular Specialist stories in December 2022 were the promising results from a postmarket surveillance study of a paclitaxel DCB; the Society for Vascular Surgery (SVS) paid tribute to the passing of former president James (Jimmy) S.T. Yao,…
ESVS AAA guidelines alert recommends ‘enhanced surveillance’ in patients treated with Nellix device
In a newly released “focused update” to their 2019 recommendations, the European Society for Vascular Surgery (ESVS) abdominal aortic aneurysm (AAA) guidelines writing committee has published advice on the surveillance and management of patients treated with the Nellix endovascular aneurysm…